CareDx, Inc., a biotechnology company headquartered in Brisbane, Australia, specializes in developing, marketing, and delivering diagnostic surveillance solutions for heart transplant recipients. The company’s mission is to transform long-term patient care in transplantation through innovative surveillance management solutions. CareDx is publicly traded on the Nasdaq stock exchange, with its initial public offering (IPO) having taken place on July 17, 2014.
As of December 18, 2025, CareDx reported no new developments. The company’s stock closed at $19.73 on December 23, 2025, which is below its 52-week high of $25.95, achieved on January 13, 2025, but above its 52-week low of $10.96, recorded on July 16, 2025. This indicates a stable trading range over the past year, with no significant volatility observed.
The company’s market capitalization stands at approximately $1.05 billion USD. Financial metrics reveal a price-to-earnings (P/E) ratio of 16.49 and a price-to-book (P/B) ratio of 3.22. These valuation multiples suggest moderate performance in terms of earnings and book value when compared to industry peers.
The most recent public disclosure from CareDx, sourced from www.wallstreet-online.de , mentions a proposed derivative settlement. However, no further corporate actions have been reported since this announcement. The stock’s price action over the past year reflects a stable, albeit modest, trading range, indicating a lack of extreme volatility.
For more information about CareDx’s products and services, interested parties can visit their website at www.xdx.com .
